 
        
        
        
                货号:A582051
                
                同义名:
                    
                        
                            
                                Dihydrobrusatol; NSC310616
                            
                        
                    
                
                
                
                    
                     
                
            
Bruceine A is a natural quassinoid compound extracted from the dried fruits of Brucea javanica (L.) and is a potential candidate for the treatment of canine babesiosis.
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 描述 | Bruceine A is a natural quassinoid compound extracted from the dried fruits of Brucea javanica (L.) and is a potential candidate for the treatment of canine babesiosis. | 
| Concentration | Treated Time | Description | References | |
| Caenorhabditis elegans reproductive tissues | 100 μM | 48 h | Evaluate the genotoxic effects of Bruceine A on reproductive tissues, showing damage to nuclear structures leading to infertility | Molecules. 2021 Dec 3;26(23):7354 | 
| ARP1 cells | 0.2 μM | 24, 48, 72 h | Evaluate the effect of BA on MM cell proliferation, results showed BA significantly inhibited MM cell proliferation. | Basic Clin Pharmacol Toxicol. 2025 Apr;136(5):e70027 | 
| primary human nasal epithelial cells (HNEpC) | 2 μM | 48 h | largely reduced SARS-CoV-2 infection | Nat Microbiol. 2023 Jan;8(1):121-134 | 
| Vero E6 cells | 1 μM | 16 h | inhibited SARS-CoV-2 replication with > 6-log reduction in viral titer | Nat Microbiol. 2023 Jan;8(1):121-134 | 
| MIA PaCa-2 cells | 0.029 μM | 24 h | Evaluate the effect of Bruceine A on the viability of MIA PaCa-2 cells, results showed Bruceine A exhibited the most potent anti-proliferation activity | Comput Struct Biotechnol J. 2021 Jun 6;19:3437-3450 | 
| primary human bronchial epithelial cells (HBEpC) | 15-200 nM | 72 h | reduced the infection even at 15 nM | Nat Microbiol. 2023 Jan;8(1):121-134 | 
| Administration | Dosage | Frequency | Description | References | ||
| NOD/SCID mice | MM Patient-Derived Tumour Xenograft (PDX) model | Intraperitoneal injection | 4 mg/kg | Twice a week until tumor diameter reached 15 mm | Evaluate the inhibitory effect of BA on MM progression, results showed BA significantly inhibited tumor growth. | Basic Clin Pharmacol Toxicol. 2025 Apr;136(5):e70027 | 
| BALB/c nude mice | Pancreatic cancer xenograft model | Intraperitoneal injection | 1 mg/kg, 2 mg/kg, 4 mg/kg | Every 2 days for 42 days | Evaluate the anti-pancreatic cancer effect of Bruceine A in vivo, results showed Bruceine A dose-dependently suppressed tumor growth and activated p38αMAPK | Comput Struct Biotechnol J. 2021 Jun 6;19:3437-3450 | 
| K18-hACE2 mice | SARS-CoV-2 infection model | Intranasal inoculation | 3.25 mg/kg | Once per day for 2 days | Reduced viral titres in the lung and brain, and protection from alveolar and peribronchial inflammation in the lung | Nat Microbiol. 2023 Jan;8(1):121-134 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 1.91mL 0.38mL 0.19mL | 9.57mL 1.91mL 0.96mL | 19.14mL 3.83mL 1.91mL | |
| CAS号 | 25514-31-2 | 
| 分子式 | C26H34O11 | 
| 分子量 | 522.54 | 
| SMILES Code | O=C([C@@]1([C@H]([C@H](O)[C@]2([H])[C@]3(C4)C)O)[C@@]([C@H](C5=O)OC(CC(C)C)=O)([H])[C@@]2([C@@](O5)([H])C[C@@]3([H])C(C)=C(O)C4=O)CO1)OC | 
| MDL No. | MFCD28167765 | 
| 别名 | Dihydrobrusatol; NSC310616 | 
| 运输 | 蓝冰 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C | 
| 溶解方案 | DMSO: 25 mg/mL(47.84 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1